Effects of Hydralazine on Tumor Blood Flow and Metabolism
Author Information
Author(s): J.C.M. Bremner, C.J.R. Counsell, G.E. Adams, I.J. Stratford, P.J. Wood, J.F. Dunn, G.K. Radda
Primary Institution: MRC Radiobiology Unit, Chilton, Didcot; MRC Biochemical and Clinical Magnetic Resonance Unit, Department of Biochemistry, Oxford
Hypothesis
The effect of hydralazine on tumors varies depending on tumor type and host.
Conclusion
Hydralazine significantly affects blood flow and metabolism in murine tumors but has minimal impact on human tumor xenografts.
Supporting Evidence
- Hydralazine caused significant changes in the Pi/total phosphate ratio in murine tumors.
- Human tumor xenografts showed little to no response to hydralazine treatment.
- Clamping the blood supply to tumors increased the Pi peak in all tumor types studied.
Takeaway
This study looked at how a drug called hydralazine affects tumors in mice. It found that the drug changes how blood flows and how tumors use energy, but it doesn't work the same way in human tumors.
Methodology
In vivo 31P nuclear magnetic resonance spectroscopy was used to study the effects of hydralazine on murine tumors and human tumor xenografts.
Limitations
The study primarily focused on murine tumors, limiting the applicability of findings to human tumors.
Participant Demographics
The study involved C3H/He mice and mutant immune suppressed nu/nu mice.
Want to read the original?
Access the complete publication on the publisher's website